1 / 36

IST-3 progress report: recruitment, baseline data and future plans

IST-3 progress report: recruitment, baseline data and future plans. Peter Sandercock on behalf of IST-3 collaborative group. UK IST-3 National Coordinators Meeting Bologna 25 th May 2005. Outline. IST-3 teams At trial co-ordinating centre, Edinburgh International Advisory Board

oleg
Download Presentation

IST-3 progress report: recruitment, baseline data and future plans

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IST-3 progress report: recruitment, baseline data and future plans Peter Sandercock on behalf of IST-3 collaborative group. UK IST-3 National Coordinators Meeting Bologna 25th May 2005

  2. Outline • IST-3 teams • At trial co-ordinating centre, Edinburgh • International Advisory Board • CT reading advisory panel • Update on recruitment, centres and countries • Baseline characteristics: are we recruiting the right sort of patients? • Future targets: importance of National Co-ordinators

  3. Co-ordinating centre people Co-principal investigators Peter Sandercock and Richard Lindley

  4. Co-ordinating centre people • Trial manager: Karen Innes • Trial Centre Manager: Alison Clark • Statistician: Steff Lewis • Data entry/management: Sheila Grant • Programming/website: Vera Soosay • Clinical Research fellow: Ingrid Kane • ACCESS study/CT reading: Joanna Wardlaw, Andrew Farrall, Eleni Sakka, David Perry

  5. IST-3 Trial Steering Committee Independent chairman Professor D Chadwick Independent members Dr P Tyrrell, Professor G Lowe (haemostasis and thrombolysis advisor), Others Professor M Dennis, Professor J Wardlaw (neuroradiology advisor) Professor C Warlow

  6. International Advisory Board National Coordinators: Australia (G Hankey & R Lindley), Austria (K Matz, M Brainin), Belgium (A Peeters), Brazil (J Fernandes), Canada (S Phillips, G Gubitz), Chile (P Lavados), China (ZM Chen M Liu), Germany (M von Reutern), Greece (K Vemmos), Hungary (D Bereczki), India (K Prasad), Italy (S Ricci), Norway (E Berge, KS Bruins), Poland (A Czlonkowska), Sweden (V Murray), Singapore (HM Chang), Slovak Republic (M Brozman), Switzerland (P Lyrer), S Africa (M Connor), Taiwan (KC Chang), UK (G Venables). National co-ordinators telconference 4th july UK thrombolysis advisor: G Ford. NINDS liaison: J Marler. ECASS-3 liaison: M Kaste. EPITHET liaison: S Davis.

  7. CT reading Advisory Panel • Chair: Joanna Wardlaw • Membership: experts in the field have been invited to become panel members • First meeting 6th October 2005 • First run of web-based CT reading system

  8. UK Funding 1999- 1999-2004 2002-6 2005-9 Norway: Norwegian Research Council Sweden: AFA Insurances, Swedish Heart & Lung Foundation Australia: Australian Heart Foundation Poland: Government of Poland Canada: funds in reserve for when approval finally granted!

  9. Resources for National Coordinators • Reimbursement of costs of postage, telephone calls, site visits for training, quality control and performing centralised follow-up. • Support from International Recruitment & Quality Control Co-ordinator, who will help provide: • support and training to new centres; • support to all centre staff working on project • help identify and recruit new centres • visit centres to monitor compliance with the protocol and procedures in random sample of patients; • attend local and regional meetings; • visit ‘problem’ centres

  10. Funding for each participating hospital • First patient recruited: We will reimburse new centres the costs of setting up the trial and getting local ethics approval by a single payment of £100 when they have successfully randomised their first patient, and the co-ordinating centre confirm that the patient fulfilled trial eligibility and have received all the initial trial data. • For each subsequent patient randomised, centres will be reimbursed £25 to cover cost of copying scans, courier postage, telephone calls and other minor expenses

  11. A note about the data The data are provisional, and changing all the time. Collaborators: please free to present/discuss these data at meetings, but please do not cite them in publications! Note: these slides will be posted on the IST-3 website after the conference for you to download

  12. New forecast

  13. Recruitment by country

  14. Baseline characteristics-are we recruiting the right sort of patients? Analyses of baseline data, based on data available on 5th May 2005 (n=342)

  15. What sort of patients do we need data on? Patients outside licence • Arriving at hospital 2-5hrs after onset • Older patients (over 80) • TACS,PACS,POCS and LACS • Severe stroke • Mild stroke • Diabetics • Prior aspirin? • Blood pressure range? • With and without ‘early ischaemia’ on pre-treatment CT scan

  16. IST-3. Baseline characteristics: hours from onset to randomisation Median = 4.0 hours

  17. Population-based study of stroke incidence (OXVASC). No of first strokes by age OXVASC Lancet 2004; 363: 1925–33

  18. IST-3. Baseline characteristics: age 120 patients aged over 80

  19. IST-3. Baseline characteristics: stroke syndrome

  20. Type of consent used by stroke syndrome

  21. IST-3. Baseline BP

  22. IST-3. Other baseline features

  23. IST-3. CT scan at baseline: randomising doctor’s opinion

  24. IST-3. CT scan at baseline: Joanna Wardlaw’s opinion *categories are not mutually exclusive: a patient may have more than one feature

  25. CASES (1135 patients treated within licence in 60 Canadian centres) vs IST-3

  26. CASES (1135 patients treated within licence in 60 Canadian centres) vs IST-3

  27. CASES: Effect of baseline features on risk and benefit of rt-PA • Baseline ASPECTS score • Strong predictor of poor outcome • But NOT a predictor of symptomatic ICH (SICH) • Age > 80 • Less likely to have good outcome • But age NOT a risk factor for ICH • Protocol violations • Predictor of SICH • But NOT a predictor of poor outcome • Low (< 1 per month) and high volume (> 1 per month) centres similar outcomes • Active lowering of BP before thrombolysis • associated with WORSE outcome • No apparent reduction in risk of SICH

  28. rt-PA in routine use: CASES. Other outcomes • Orolingual angioedema = 1.3% (related to frequent use of ACE inhibitors?) • All managed conservatively, except: • 1 intubated, 1 cricothyroidotomy • Acute hypotension during rt-PA infusion = 0.4% • Managed with crystalloid infusion

  29. Are we recruiting the right sort of patients? • Arriving at hospital 2-5hrs after onset YES • Older patients (over 80) YES • TACS:YES, PACS,POCS & LACS: NEED MORE! • Severe stroke: YES • Mild stroke: NEED MORE! • Diabetics: YES • Prior aspirin: YES • Blood pressure range: YES • Some ‘early ischaemia’ on pre-treatment CT:YES

  30. Data Monitoring Committee report (3.9.04) ‘The independent Data Monitoring Committee (Professors Collins, van Gijn & Bath) was provided on 20th August 2004 with the unblinded interim analysis for 253 randomised patients in the IST-3 trial. These analyses included information about the primary outcomes of death and disability, as well as about specific fatal and non-fatal events (including intracranial haemorrhage). Following review of these analyses, the DMC considers that it remains important for IST-3 to continue as planned. Consequently, we encourage you strongly in your efforts to increase the rate of recruitment to the trial, which appears to be progressing well.

  31. Recruitment targets Increase recruitment 10x • Increase active centres from 23 to 200 • Increase recruitment from 35 patients per 3 months to 350 per 3 months • Final target = 6000 patients Continue to recruit similar patients • within 3 hours: the type of patients who do not exactly fit the conditions of the licence, but who might benefit from rt-PA • 3-6 hours:in patients where you consider thrombolysis is promising but unproven.

  32. Targets for number of new centres • To achieve our target of 200 active centres, we will need to start about 250 centres. • The National co-ordinator in each country will be responsible for recruiting new centres. • At the start of the MRC phase, we expect to have 50 centres, and we aim to activate an average of 55 centres per year over 2004-8 (more than this in years 1 & 2).

  33. Summary to date • Recruitment of patients is going well • But need to increase it 10-fold • Recruiting correct type of patients • Results will be clinically very important • Other active countries: • Keep up the good work/excellent data quality! • Seek to recruit less severe strokes • Keep up the work of recruiting new centres • New countries: • Try and recruit your first patient! • Tell everyone in your country about the trial • Publicise the trial • Encourage well organised centres to join

More Related